Application of the Academic Research Consortium High Bleeding Risk Criteria in an All-Comers Registry of Percutaneous Coronary Intervention

Masahiro Natsuaki(Saga University), Satoshi Shizuta(Kyoto University), Takao Kato(Kyoto University), Yutaka Furukawa(Kobe City Medical Center General Hospital), Kenji Andò(Kokura Memorial Hospital), Hiroki Shiomi(Kyoto University), Hirotoshi Watanabe(Kyoto University), Kazuya Nagao(Nagaoka Red Cross Hospital), Kazushige Kadota(Kurashiki Central Hospital), Yoshihisa Nakagawa(Tenri Hospital), Takeshi Morimoto(Hyogo Medical University), Mamoru Toyofuku(Japanese Red Cross Society Wakayama Medical Center), Takeshi Kimura(Kyoto University), Kyohei Yamaji(Kokura Memorial Hospital), Tomohisa Tada(Shizuoka General Hospital)
Circulation Cardiovascular Interventions
November 1, 2019
10.1161/circinterventions.119.008307
Cited by 135

Related Papers

Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI
|JAMA|2019|830
JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease
|Circulation Journal|2020|345
The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease
|Thrombosis and Haemostasis|2020|334
Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome
|JAMA Cardiology|2022|296
A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial
|The Lancet|2018|288